SI
SI
discoversearch

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor.  We ask that you disable ad blocking while on Silicon Investor in the best interests of our community.  If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.
Biotech / Medical : Trimeris (TRMS)
 Public ReplyPrvt ReplyMark as Last ReadFilePrevious 10Next 10PreviousNext  
To: David S. who started this subject4/21/2004 9:14:37 AM
From: Doc Bones   of 108
 
08:31 TRMS Trimeris upped to Buy from Neutral at First Albany (14.30 )

First Albany upgrades TRMS to Buy from Neutral based on signs of fundamental improvement in the co's Q1 results; firm says Fuzeon sales totaled $24.0 mln worldwide, which was stronger than their est of $21 mln, and the co described a number of strategic programs that are likely to help Fuzeon gain acceptance. In addition, although they do not expect sales to accelerate dramatically, they think the modest signs of improvement coupled with lowered expectations and a markedly lower mkt value suggest that the stock may have reached bottom. Target is $18.
Report TOU ViolationShare This Post
 Public ReplyPrvt ReplyMark as Last ReadFilePrevious 10Next 10PreviousNext  

HomeMailHotSubjectMarksPeopleMarksKeepersSettings
Terms Of UseContact UsCopyright/IP PolicyPrivacy PolicyAbout UsFAQAdvertise on SI
© 2026 Knight Sac Media.  Data provided by Twelve Data, Alpha Vantage, and CityFALCON News